MedTrace Logo

Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

NCT01944774 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2025-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with community-acquired pneumonia (CAP).

Conditions

Interventions

DRUG

Nemonoxacin 500 mg

IV Infusion, once daily for 7\~14 days

DRUG

Nemonoxacin 650 mg

IV Infusion, once daily for 7\~14 days

DRUG

Moxifloxacin 400 mg

IV Infusion, once daily for 7\~14 days

Sponsors & Collaborators

  • QPS-Qualitix

    collaborator INDUSTRY

  • R&G Pharma Studies Co.,Ltd.

    collaborator INDUSTRY

  • TaiGen Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • LiWen Chang · Taigenbiotech

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • China
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944774 on ClinicalTrials.gov